The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.

, , , , , , , , , , , ,,
Nature Reviews Clinical Oncology
Erasmus MC: University Medical Center Rotterdam

Eggermont, A. (2009). Immunotherapy: Vaccine trials in melanoma -- time for reflection. Nature Reviews Clinical Oncology, 6(5), 256–258. doi:10.1038/nrclinonc.2009.42